High-dose chemotherapy with autologous hematopoietic stem cell transplantation in patients with multiple myeloma

Research output: Contribution to journalReview articlepeer-review

18 Scopus citations

Abstract

Multiple myeloma, for all practical purposes, remains an incurable malignancy; however, 5-year survival has improved substantially during the past 30 years. A major contribution to improved outcome is the use of high-dose chemotherapy and stem cell transplantation. This multifaceted approach to therapy requires an understanding of appropriate induction therapy, techniques for stem cell mobilization, appropriate conditioning and supportive care. Also of importance are prognosis, features that predict outcome, the suitability of transplant candidates, and post-transplantation maintenance therapy.

Original languageEnglish (US)
Pages (from-to)343-360
Number of pages18
JournalExpert review of anticancer therapy
Volume6
Issue number3
DOIs
StatePublished - Mar 1 2006

Keywords

  • Age
  • Multiple myeloma
  • Renal failure
  • Stem cell transplantation
  • Survival

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'High-dose chemotherapy with autologous hematopoietic stem cell transplantation in patients with multiple myeloma'. Together they form a unique fingerprint.

Cite this